Description

Product Description

Delmitide (CAS 287096-87-1), also known as RDP58, is a synthetic decapeptide designed using D-amino acids to enhance oral bioavailability and metabolic stability. Unlike conventional peptides composed of L-amino acids, Delmitide’s D-isomer configuration renders it resistant to gastrointestinal enzymatic degradation, making it suitable for oral administration in experimental models.

Functionally, Delmitide is a selective anti-inflammatory agent. It acts by suppressing the production of pro-inflammatory cytokines—notably tumor necrosis factor-alpha (TNF-?), interferon-gamma (IFN-?), and interleukin-12 (IL-12)—while simultaneously up-regulating heme oxygenase-1 (HO-1), a cytoprotective and anti-inflammatory enzyme. This dual regulatory activity enables Delmitide to rebalance immune homeostasis without broadly suppressing immune function, which is a major advantage over many immunosuppressive agents.

Delmitide was originally developed to explore novel therapeutic strategies for inflammatory bowel diseases (IBD), especially ulcerative colitis (UC). Preclinical studies demonstrated significant efficacy in reducing mucosal inflammation, promoting epithelial repair, and restoring barrier function in gastrointestinal models.

Beyond ulcerative colitis, Delmitide’s mechanism of action has expanded its application into broader research areas, including:

• Crohn’s disease models

• Rheumatoid arthritis (RA)

• Psoriasis and skin inflammation

• Systemic inflammatory syndromes

Compared with traditional small-molecule anti-inflammatory drugs, Delmitide provides:

• Higher specificity for cytokine regulation.

• Reduced systemic toxicity due to its peptide-based nature.

• Oral activity, which distinguishes it from many peptide agents requiring parenteral administration.

In summary, Delmitide represents a next-generation immunomodulatory research tool. Its ability to finely tune cytokine production and activate protective stress-response pathways makes it valuable for academic and translational research into chronic inflammatory and autoimmune diseases.

Product Specifications

Extended Notes:
Delmitide’s D-isomer peptide design dramatically improves oral stability. Its anti-inflammatory selectivity offers researchers a unique tool for studying cytokine-driven immune responses without broad immunosuppression. This makes it particularly attractive in in vivo gastrointestinal models where oral dosing is critical.

Mechanism of Action & Research Applications

Mechanism of Action
Delmitide works by modulating the cytokine regulatory network. Its key activities include:

• Inhibition of TNF-? ? Prevents inflammatory cascades, reduces mucosal inflammation.

• Suppression of IFN-? ? Limits Th1-driven immune responses in autoimmune conditions.

• Reduction of IL-12 ? Weakens pro-inflammatory T cell differentiation.

• Up-regulation of HO-1 ? Promotes cytoprotection, antioxidant activity, and tissue repair.

This combination results in balanced immune suppression and cytoprotection, minimizing collateral tissue damage while preserving basal immune defense.

Research Applications

1. Ulcerative Colitis Research

   • Reduces colonic mucosal damage and restores epithelial barrier function.

   • Oral availability enables clinically relevant dosing studies.

2. Crohn’s Disease & IBD Models

   • Suppresses TNF-? and IFN-? mediated intestinal inflammation.

   • Serves as a model compound for peptide-based oral IBD therapies.

3. Rheumatoid Arthritis & Autoimmune Diseases

   • Demonstrates efficacy in preventing joint destruction by reducing cytokine storms.

4. Dermatology & Psoriasis

   • Regulates inflammatory cytokines contributing to keratinocyte overproliferation.

5. Systemic Inflammation & Sepsis

   • Potential to modulate systemic cytokine storms through selective suppression.

6. Pharmacological Research

   • A model compound for studying oral peptide stability and cytokine-targeted peptide therapies.

     

Side Effects (For Reference in Research Models)

In preclinical research, Delmitide is generally well tolerated. However, some dose-related and context-dependent effects have been reported:

• Potential gastrointestinal effects (mild irritation at very high oral doses).

• Altered cytokine balance leading to increased susceptibility to certain infections.

• Possible hepatotoxicity in long-term, high-dose studies.

• Immune suppression artifacts in models requiring intact Th1 responses.

• Formulation-dependent variability, especially in oral vs parenteral administration.

Researchers should optimize dosage, monitor cytokine profiles, and apply appropriate controls to account for immunomodulatory variability.

Disclaimer

For research use only. Not for human or veterinary use.

Keywords

• Delmitide CAS 287096-87-1

• Delmitide supplier

• Delmitide GMP manufacturer

•  ulcerative colitis research

•  peptide anti-inflammatory

•  cytokine inhibitor

•  HO-1 activator

• Buy Delmitide bulk